Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention

• Published in: Medicina (Kaunas, Lithuania) Vol. 57; no. 1; p. 59
• Main Author: Wiśniewski, Adam
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 10.01.2021; MDPI AG
• Subjects: aspirin; Aspirin - therapeutic use; Biological Availability; clopidogrel; Clopidogrel - therapeutic use; Drug Interactions; Drug Resistance - genetics; Drug Resistance - physiology; Humans; ischemic stroke; Ischemic Stroke - prevention & control; Kidney Failure, Chronic - physiopathology; Metabolic Syndrome - physiopathology; molecular pathology; Pharmacogenomic Variants - genetics; Platelet Activation; Platelet Aggregation Inhibitors - therapeutic use; Platelet Function Tests; platelets; resistance; Review; Risk Assessment; Secondary Prevention; Smoking - physiopathology; Stroke - prevention & control; clopidogrel; low biological response; aspirin; platelet reactivity; antiplatelet therapy; platelet function; molecular pathology; ischemic stroke; platelets; resistance

Effective platelet inhibition is the main goal of the antiplatelet therapy recommended as a standard treatment in the secondary prevention of non-embolic ischemic stroke. Acetylsalicylic acid (aspirin) and clopidogrel are commonly used for this purpose worldwide. A low biological response to antipla...